Effectiveness of eradication therapy for Hp infection of residents of Perm and the Perm region

Author:

Vologzanina L. G.1ORCID,Igumnova O. A.1ORCID,Petuhova I. V.1

Affiliation:

1. “GASTROCENTR” LTD

Abstract

Purpose: to evaluate the effectiveness of eradication therapy for Hp infection in Perm and the Perm region. Materials and methods: a retrospective analysis of 88 case histories of patients who underwent eradication of Hp infection was carried out at the Perm Medical Center (GASTROCENTER). Primary infection with H. pylori was confirmed by: serological blood test or determination of Hp antigen in feces, rapid urease test, and C13 urease breath test. Hp eradication therapy regimens, depending on the source of prescription, included standard triple therapy with the addition of bismuth preparations for a period of 14 days (main group) or 7-10-day triple therapy (control group). Results and discussion: the main indications for Hp eradication were: chronic gastritis and gastroesophageal reflux disease. In the main group, all patients received Hp eradication therapy with the inclusion of: esomeprazole (emanera) 40 mg, amoxicillin 1000 mg, clarithromycin (fromilid) 50 mg and bismuth tripotassium dicitrate (ulcavis) 240 mg twice a day for 14 days. The control group included patients who received Hp eradication schemes with various proton pump inhibitors, amoxicillin and clarithromycin or metronidazole or levofloxacin or even rifaximin for 7 or 10 days. Adverse events: abdominal pain and diarrhea occurred in both groups. Patients of the main group complained about bitterness in the mouth, where all patients received clarithromycin. Approximately the same small number of patients complained of nausea. With a differentiated assessment by groups, in the main group, Hp eradication was highly effective and reached 93%, while in the control group it was significantly lower and did not exceed 48% (p=0,00087) Conclusions: modern detection of Hp infection and its eradication is an effective approach to the prevention of atrophic gastritis, gastric cancer and peptic ulcer of the stomach and duodenum. The “gold” standard for diagnosing Hp infection is the 13C-urease breath test. For residents of Perm and the Perm Territory, it is recommended to use Hp eradication with the appointment of a 14-day regimen with the inclusion of esomeprazole (Emaner), clarithromycin (Fromilide), amoxicillin and bismuth tripotassium dicitrate (Ulkavis) as the first line of therapy.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference47 articles.

1. Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):4-21. (In Russ.) doi: 10.22416/1382-4376-2017-27-4-4-21.@@ Ivashkin V. T., Maev I. V., Lapina T. L., Sheptulin A. A., Trukhmanov A. S., Abdulkhakov R. A., Alekseenko S. A., Dekhnich N. N., Kozlov R. S., Klyaritskaya I. L., Kurilovich S. A., Osipenko M. F., Simanenkov V. I., Khlynov I. B. Lechenie infektsii Helicobacter pylori: meinstrim i novatsii (Obzor literatury i rezolyutsiya Ekspertnogo soveta Rossiiskoi gastroenterologicheskoi assotsiatsii 19 maya 2017 g.). Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(4):4-21. doi: 10.22416/1382-4376-2017-27-4-4-21.

2. Maev I. V., Samsonov A. A., Andreev D. N. et al. Clinical significance of Helicobacter pylori infection. Clinical Medicine. 2013; 8:4-12. (in Russ.)@@ Maev I. V., Samsonov A. A., Andreev D. N. i dr. Klinicheskoe znachenie infektsii Helicobacter pylori // Klinicheskaya meditsina. 2013; 8: 4-12.

3. Shey W.D., Leonitiadis G. I., Howden C. W., Moss S. F. ACG clinical guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 1123:212-38.

4. Tkach S.M., Onischuk L. A. Proton pump inhibitors and the risk of drug-drug interactions. Gastroenterology. 2015;2 (56):91-98. (in Russ.)@@ Tkach S. M., Onishchuk L. A. Ingibitory protonnoi pompy i risk mezhlekarstvennykh vzaimodeistvii Gastroenterologіya № 2 (56) • 2015 s 91-98.

5. Tolstokorov A.S., Dergunova S. A., Alexandrov D. A. The role of helicobacteriosis in the development of stomach diseases. Innovative science. 2019;(6):191-194. (in Russ.)@@ Tolstokorov A. S., Dergunova S. A., Aleksandrov D. A. Rol' khelikobakterioza v razvitii zabolevanii zheludka. Innovatsionnaya nauka № 6 / 2019 191-194

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3